Unlocking the portable potential of Dried Blood Spot sampling with hemaPEN™
Photo: Dr Florian Lapierre, ASTech Post-doctoral Research Fellow from UTAS, currently undertaking his industry placement at Trajan Scientific and Medical - developing the hemaPEN to change the way individuals have their blood tested.

Unlocking the portable potential of Dried Blood Spot sampling with hemaPEN™

  • Post Category:hemaPEN / News
2 September 2015

Harnessing the benefits of Dried Blood Spot (DBS) sampling in an intuitive and safe portable format, hemaPEN has the potential to change the way individuals have their blood tested – eliminating the need to visit a clinic and offering precision blood sampling with the click of a button via its familiar pen design, which can be easily used by anyone including the young, elderly and people with disabilities. 

The hemaPEN is the only device of its kind in the world that allows people to collect an uncontaminated and precise volume of their own blood from the fingertip at home, eliminating the need to travel to a medical clinic – not only saving time, but the superior ready-to-use DBS sample enables the laboratory to deliver more definitive test results.

hemaPEN is the first product concept from ASTech, the ARC Training Centre for Portable Analytical Separation Technologies – a $5.2 M program part funded by the Australian Research Council (ARC), University of Tasmania (UTAS) and Trajan – and has huge potential to benefit to a range of disease screening including diabetes, therapeutic drug monitoring and medical research.

ASTech Training Centre Director Professor Emily Hilder said the development of this first prototype was the first of many innovations to come.

“At ASTech we are already seeing the outcomes of applying academic research to real-life applications,” said Professor Hilder.

ASTech researchers have access to University of Tasmania’s extensive facilities for separation science, as well as the opportunity to undertake industry placements with Trajan, or Trajan’s commercial partners.

The opportunity for our researchers to be immersed in a commercial setting adds new perspectives during product development.

The hemaPEN concept will be further developed through market testing.

“It has the potential to set new standards in the pathology industry, with the ability to deliver precision blood microsamples for more
accurate analytical outcomes – meaning more definitive results for patients, said Professor Hilder.

More information on hemaPEN and media contact details